Hospital Acquired PneumoniaNCT07745491
Pneumonia After Cardiovascular Surgery With Artificial Intelligence
An observational study of Hospital Acquired Pneumonia, run by Tomsk National Research Medical Center of the Russian Academy of Sciences at 1 site in Russia.
Trial summary
This multicenter, prospective, observational study aims to address two primary objectives. The first objective is to demonstrate that hospital-acquired pneumonia (nosocomial pneumonia) following cardiac surgery can be predicted using artificial intelligence (AI), and to develop a personalized risk calculator for its… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hospital Acquired Pneumonia
- What is being tested?
- Not applicable- observational study
- How many people
- 700 participants
- Where
- 1 siteRussia
- Study dates
- 29 Jul 2026to 30 Sep 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients of 18 years and older after cardiac and/or vascular surgical intervention during the current hospitalization
Who may be able to join
- Age ≥ 18 years;
- Cardiac and/or vascular surgical intervention during the current hospitalization;
- Signed informed consent from the patient for the use of their anonymized data for scientific purposes.
Who cannot join
- Use of systemic antibacterial drugs within 30 days prior to the surgical intervention;
- Prescription of systemic antibacterial drugs during the hospitalization period for any indication other than hospital-acquired pneumonia;
- HIV infection.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
Tomsk
Tatiana P. Kalashnikova, MD, PhD, +7 913 8141664, kalashnikova-t@mail.ru
About this study
Official title: Hospital-acquired Pneumonia After Cardiovascular Surgery (CS): the Prediction and Assessment of Long-term Cardiovascular and Pulmonary Outcomes With Artificial Intelligence (AI) - (PNEUMONIA-CS-AI)
This multicenter, prospective, observational study aims to address two primary objectives.
The first objective is to demonstrate that hospital-acquired pneumonia (nosocomial pneumonia) following cardiac surgery can be predicted using artificial intelligence (AI), and to develop a personalized risk calculator for its development.
Read more
The second objective is to demonstrate that hospital-acquired pneumonia can serve as a risk factor for a 1-year composite cardiovascular and pulmonary outcome after cardiac surgery, and to develop a personalized risk calculator for this composite outcome.
The composite outcome will include the occurrence of any of the following events:
- Respiratory death
- Hospitalization for respiratory diseases
- Development of oxygen dependence
- New-onset asthma, COPD, or interstitial lung disease
- Initiation or intensification of bronchodilator or corticosteroid therapy
- Cardiovascular death
- Acute myocardial infarction
- Unstable angina
- Myocardial revascularization
- Acute ischemic stroke
- Transient ischemic attack
- Acute heart failure
- Hospitalization for decompensated heart failure
- New-onset atrial fibrillation or ventricular tachycardia
- Initiation or intensification of antiarrhythmic therapy Both objectives will be addressed using artificial intelligence technologies applied during the data analysis phase.
This is a non-interventional study. Patient evaluation and treatment are conducted in strict accordance with approved standards of medical care for the respective conditions. No experimental or unregistered (not approved for use in the Russian Federation) medical or diagnostic procedures will be performed during this study.
Read the detailed description
Hospital-acquired pneumonia (nosocomial pneumonia) is one of the most common complications following cardiac and/or vascular surgery, with an incidence reaching up to 37% after certain types of procedures. This complication is associated with prolonged hospital stays, increased healthcare costs, and higher mortality rates both during hospitalization and within 5 years post-surgery. To determine the necessity of implementing additional personalized preventive measures against pneumonia, it is clinically valuable to assess the probability of its development in each individual patient. A medical risk calculator, which enables the calculation of an individual's risk of developing pneumonia, can serve as a supportive tool for clinical decision-making.
This is an observational study. Patient evaluation and treatment will be conducted in strict accordance with approved standards of medical care for the respective conditions. No experimental or unregistered (not approved for use) medical or diagnostic methods will be utilized in this study.
The study involves the systematic collection of data from the medical records of patients who undergo cardiac and/or vascular surgery during their current hospitalization. These data will be analyzed using artificial intelligence (AI) technologies, including machine learning methods such as gradient boosting, random forest, neural networks, Bayesian networks, and others.
This is a multicenter study involving three participating centers: Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk State University, and the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases.
In phase 1, data will be collected from at least 400 patients undergoing cardiac surgery at a single center (Tomsk National Research Medical Center of the Russian Academy of Sciences). An anonymized database will be created, including the following parameters:
- Demographic and anthropometric characteristics (age, sex, height, weight, body mass index)
- Smoking status, including duration and intensity (pack-years)
- Comorbidities, including chronic obstructive pulmonary disease (COPD), diabetes mellitus, chronic kidney disease (CKD), prior myocardial infarction, and atrial fibrillation
- Preoperative left ventricular ejection fraction (LVEF)
- Preoperative pulmonary function test (PFT) parameters
- Preoperative length of hospital stay
- Intraoperative variables, including type of surgery, use and duration of cardiopulmonary bypass (CPB), volume of blood loss, blood component transfusion, duration of mechanical ventilation, and other relevant surgical details
- Perioperative laboratory data, including hemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, platelet count, serum creatinine, and creatine phosphokinase (CPK) Subsequently, the occurrence or non-occurrence of hospital-acquired pneumonia will be documented within 30 days post-surgery. Additionally, other relevant clinical data regarding the course of the postoperative period will be collected.
Phase 2 will be conducted jointly by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, focusing on data processing and analysis. This phase will include:
- Data integrity assessment and quality control
- Missing data imputation (handling of missing values)
- Development of predictive models for hospital-acquired pneumonia using multivariate binary logistic regression (SPSS version 26.0) and machine learning algorithms, including Bayesian networks, decision trees, random forest, gradient boosting, and recurrent neural networks (RNN).
Phase 3, also performed by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, involves the evaluation and comparison of the developed predictive models. The models will be compared based on key performance metrics:
- Accuracy, sensitivity, and specificity
- Interpretability
- Robustness to overfitting and data incompleteness Based on this evaluation, the preferred predictive model for hospital-acquired pneumonia demonstrating optimal performance characteristics will be selected.
Phase 4 (conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University) will focus on the development of a universal medical risk calculator. This tool will determine the individual probability of developing hospital-acquired pneumonia following any type of cardiac and/or vascular surgical intervention. The calculator will be constructed by selecting key predictors and evaluating the feature weights (coefficients) derived from the best-performing predictive model identified in Phase 3.
Phase 5 will involve the internal validation of the developed risk calculator. This phase will consist of the following steps:
- Prospective enrollment of an additional 200 patients into the observational study at the primary center (Tomsk National Research Medical Center of the Russian Academy of Sciences).
- Preoperative assessment of the individual risk (probability) of hospital-acquired pneumonia for each patient using the newly developed calculator.
- Surgical intervention followed by a 30-day postoperative observation period.
- Calibration and performance analysis by comparing the pre-test (predicted) probability of pneumonia with the actual observed postoperative outcomes.
Phase 6 will involve the external validation of the developed medical risk calculator across 1 to 3 cardiovascular surgery centers. Each participating center will conduct an evaluation identical to Phase 5, prospectively enrolling data from at least 100 patients. Initially, the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases will join the study, with the potential inclusion of additional medical centers at a later stage.
Phase 7 (conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases) aims to evaluate the impact of hospital-acquired pneumonia on the development of clinical outcomes within 12 months post-cardiac surgery. These outcomes include:
- Primary composite cardiovascular and pulmonary outcome
- Secondary composite pulmonary outcome
- Secondary composite cardiovascular outcome
This phase will be conducted by gathering follow-up data from enrolled patients or their next of kin via in-person visits, telephone interviews, medical record reviews, or centralized electronic healthcare registries. Data will be collected on whether patients experienced any of the following events within 12 months after surgery:
- Pulmonary / Respiratory Events: Respiratory death, hospitalization for respiratory diseases, development of oxygen dependence, new-onset asthma, COPD, or interstitial lung disease, and initiation or intensification of bronchodilator or corticosteroid therapy.
- Cardiovascular Events: Cardiovascular death, acute myocardial infarction, unstable angina, myocardial revascularization, acute ischemic stroke, transient ischemic attack (TIA), acute heart failure, hospitalization for decompensated heart failure, new-onset atrial fibrillation or ventricular tachycardia, and initiation or intensification of antiarrhythmic therapy.
Phase 8 will be conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, focusing on the processing and analysis of the 12-month follow-up data. This final phase will include:
- Data integrity assessment and quality control.
- Missing data imputation for the long-term follow-up variables.
- Comparative analysis of the incidence of cardiovascular and pulmonary events within 12 months post-surgery between patients who developed hospital-acquired pneumonia during the early postoperative period and those who did not.
- Development of predictive models for the study's composite endpoints, utilizing both standard statistical methods and artificial intelligence (AI) / machine learning algorithms.
- Conditions
- Hospital Acquired Pneumonia
- Being tested
- Not applicable- observational study
- Keywords
- Hospital acquired pneumonia, Risk factors, Composite Cardiovascular and Pulmonary outcomes
- Medical subject headings
- Healthcare-Associated Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Not applicable- observational studyOther
Not applicable- observational study
| Study group | Role | What they receive |
|---|---|---|
| Patients after cardiovascular surgery | Patients of 18 years and older, after cardiac and/or vascular surgical intervention during the current hospitalization, who signed informed consent for the use of their anonymized data for scientific purposes Receives: Other: Not applicable- observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hospital acquired pneumonia
Occurrence of hospital-acquired pneumonia
Measured: Within 30 days post-surgery
Composite cardiovascular and pulmonary endpoint
Occurrence of the composite cardiovascular and pulmonary endpoint
Measured: 12 months post-surgery
Secondary outcomes (3)
Non-pneumonia postoperative complications
Incidence of non-pneumonia postoperative complications (surgical site infections, cardiac events, etc.)
Measured: Within 30 days post-surgery
Composite Pulmonary Outcome
Incidence of the Composite Pulmonary Outcome:
Respiratory death; Hospitalization due to respiratory diseases; New-onset oxygen dependence; New-onset asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease (ILD); Initiation or intensification of bronchodilator or corticosteroid therapy
Measured: 12 months post-surgery
Composite Cardiovascular Outcome
Incidence of the Composite Cardiovascular Outcome:
Cardiovascular death; Acute myocardial infarction; Unstable angina; Myocardial revascularization; Acute ischemic stroke (acute cerebrovascular accident); Transient ischemic attack (TIA); Acute heart failure; Hospitalization for decompensated heart failure; New-onset atrial fibrillation or ventricular tachycardia; Initiation or intensification of antiarrhythmic therapy
Measured: 12 months post-surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2026
- Study start29 Jul 2026
- Primary completion30 Oct 2026 (estimated)
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hospital Acquired PneumoniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 700 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- National Research Tomsk State University, Research Institute for Complex Problems of Cardiovascular Diseases, Russia
- Responsible party
- Sponsor
- Investigators
- Alla A. Boshchenko, MD, PhD, DSc, Study director, Cardiology Research Institute of Tomsk NRMCTatiana P. Kalashnikova, MD, PhD, Principal investigator, Cardiology Research Institute of Tomsk NRMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07745491
- Sponsor's protocol ID
- CRI-253/2
- Status last verified
- Aug 2026
- First submitted
- 29 Jul 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hospital-acquired Pneumonia After Cardiovascular Surgery (CS): the Prediction and Assessment of Long-term Cardiovascular and Pulmonary Outcomes With Artificial Intelligence (AI) - (PNEUMONIA-CS-AI)
- ClinicalTrials.gov ID
- NCT07745491
- Acronym / sponsor ID
- CRI-253/2
- Conditions
- Hospital Acquired Pneumonia
- Keywords
- Hospital acquired pneumonia, Risk factors, Composite Cardiovascular and Pulmonary outcomes
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- Tomsk National Research Medical Center of the Russian Academy of SciencesUniversity, hospital or other
- Collaborators
- National Research Tomsk State University, Research Institute for Complex Problems of Cardiovascular Diseases, Russia
- Study start
- 29 Jul 2026 (actual)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 4 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter, prospective, observational study aims to address two primary objectives.
The first objective is to demonstrate that hospital-acquired pneumonia (nosocomial pneumonia) following cardiac surgery can be predicted using artificial intelligence (AI), and to develop a personalized risk calculator for its development.
The second objective is to demonstrate that hospital-acquired pneumonia can serve as a risk factor for a 1-year composite cardiovascular and pulmonary outcome after cardiac surgery, and to develop a personalized risk calculator for this composite outcome.
The composite outcome will include the occurrence of any of the following events:
- Respiratory death
- Hospitalization for respiratory diseases
- Development of oxygen dependence
- New-onset asthma, COPD, or interstitial lung disease
- Initiation or intensification of bronchodilator or corticosteroid therapy
- Cardiovascular death
- Acute myocardial infarction
- Unstable angina
- Myocardial revascularization
- Acute ischemic stroke
- Transient ischemic attack
- Acute heart failure
- Hospitalization for decompensated heart failure
- New-onset atrial fibrillation or ventricular tachycardia
- Initiation or intensification of antiarrhythmic therapy Both objectives will be addressed using artificial intelligence technologies applied during the data analysis phase.
This is a non-interventional study. Patient evaluation and treatment are conducted in strict accordance with approved standards of medical care for the respective conditions. No experimental or unregistered (not approved for use in the Russian Federation) medical or diagnostic procedures will be performed during this study.
Detailed description
Hospital-acquired pneumonia (nosocomial pneumonia) is one of the most common complications following cardiac and/or vascular surgery, with an incidence reaching up to 37% after certain types of procedures. This complication is associated with prolonged hospital stays, increased healthcare costs, and higher mortality rates both during hospitalization and within 5 years post-surgery. To determine the necessity of implementing additional personalized preventive measures against pneumonia, it is clinically valuable to assess the probability of its development in each individual patient. A medical risk calculator, which enables the calculation of an individual's risk of developing pneumonia, can serve as a supportive tool for clinical decision-making.
This is an observational study. Patient evaluation and treatment will be conducted in strict accordance with approved standards of medical care for the respective conditions. No experimental or unregistered (not approved for use) medical or diagnostic methods will be utilized in this study.
The study involves the systematic collection of data from the medical records of patients who undergo cardiac and/or vascular surgery during their current hospitalization. These data will be analyzed using artificial intelligence (AI) technologies, including machine learning methods such as gradient boosting, random forest, neural networks, Bayesian networks, and others.
This is a multicenter study involving three participating centers: Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk State University, and the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases.
In phase 1, data will be collected from at least 400 patients undergoing cardiac surgery at a single center (Tomsk National Research Medical Center of the Russian Academy of Sciences). An anonymized database will be created, including the following parameters:
- Demographic and anthropometric characteristics (age, sex, height, weight, body mass index)
- Smoking status, including duration and intensity (pack-years)
- Comorbidities, including chronic obstructive pulmonary disease (COPD), diabetes mellitus, chronic kidney disease (CKD), prior myocardial infarction, and atrial fibrillation
- Preoperative left ventricular ejection fraction (LVEF)
- Preoperative pulmonary function test (PFT) parameters
- Preoperative length of hospital stay
- Intraoperative variables, including type of surgery, use and duration of cardiopulmonary bypass (CPB), volume of blood loss, blood component transfusion, duration of mechanical ventilation, and other relevant surgical details
- Perioperative laboratory data, including hemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, platelet count, serum creatinine, and creatine phosphokinase (CPK) Subsequently, the occurrence or non-occurrence of hospital-acquired pneumonia will be documented within 30 days post-surgery. Additionally, other relevant clinical data regarding the course of the postoperative period will be collected.
Phase 2 will be conducted jointly by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, focusing on data processing and analysis. This phase will include:
- Data integrity assessment and quality control
- Missing data imputation (handling of missing values)
- Development of predictive models for hospital-acquired pneumonia using multivariate binary logistic regression (SPSS version 26.0) and machine learning algorithms, including Bayesian networks, decision trees, random forest, gradient boosting, and recurrent neural networks (RNN).
Phase 3, also performed by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, involves the evaluation and comparison of the developed predictive models. The models will be compared based on key performance metrics:
- Accuracy, sensitivity, and specificity
- Interpretability
- Robustness to overfitting and data incompleteness Based on this evaluation, the preferred predictive model for hospital-acquired pneumonia demonstrating optimal performance characteristics will be selected.
Phase 4 (conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University) will focus on the development of a universal medical risk calculator. This tool will determine the individual probability of developing hospital-acquired pneumonia following any type of cardiac and/or vascular surgical intervention. The calculator will be constructed by selecting key predictors and evaluating the feature weights (coefficients) derived from the best-performing predictive model identified in Phase 3.
Phase 5 will involve the internal validation of the developed risk calculator. This phase will consist of the following steps:
- Prospective enrollment of an additional 200 patients into the observational study at the primary center (Tomsk National Research Medical Center of the Russian Academy of Sciences).
- Preoperative assessment of the individual risk (probability) of hospital-acquired pneumonia for each patient using the newly developed calculator.
- Surgical intervention followed by a 30-day postoperative observation period.
- Calibration and performance analysis by comparing the pre-test (predicted) probability of pneumonia with the actual observed postoperative outcomes.
Phase 6 will involve the external validation of the developed medical risk calculator across 1 to 3 cardiovascular surgery centers. Each participating center will conduct an evaluation identical to Phase 5, prospectively enrolling data from at least 100 patients. Initially, the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases will join the study, with the potential inclusion of additional medical centers at a later stage.
Phase 7 (conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases) aims to evaluate the impact of hospital-acquired pneumonia on the development of clinical outcomes within 12 months post-cardiac surgery. These outcomes include:
- Primary composite cardiovascular and pulmonary outcome
- Secondary composite pulmonary outcome
- Secondary composite cardiovascular outcome
This phase will be conducted by gathering follow-up data from enrolled patients or their next of kin via in-person visits, telephone interviews, medical record reviews, or centralized electronic healthcare registries. Data will be collected on whether patients experienced any of the following events within 12 months after surgery:
- Pulmonary / Respiratory Events: Respiratory death, hospitalization for respiratory diseases, development of oxygen dependence, new-onset asthma, COPD, or interstitial lung disease, and initiation or intensification of bronchodilator or corticosteroid therapy.
- Cardiovascular Events: Cardiovascular death, acute myocardial infarction, unstable angina, myocardial revascularization, acute ischemic stroke, transient ischemic attack (TIA), acute heart failure, hospitalization for decompensated heart failure, new-onset atrial fibrillation or ventricular tachycardia, and initiation or intensification of antiarrhythmic therapy.
Phase 8 will be conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, focusing on the processing and analysis of the 12-month follow-up data. This final phase will include:
- Data integrity assessment and quality control.
- Missing data imputation for the long-term follow-up variables.
- Comparative analysis of the incidence of cardiovascular and pulmonary events within 12 months post-surgery between patients who developed hospital-acquired pneumonia during the early postoperative period and those who did not.
- Development of predictive models for the study's composite endpoints, utilizing both standard statistical methods and artificial intelligence (AI) / machine learning algorithms.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients after cardiovascular surgery | – | Other: Not applicable- observational studyPatients of 18 years and older, after cardiac and/or vascular surgical intervention during the current hospitalization, who signed informed consent for the use of their anonymized data for scientific purposes |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients of 18 years and older after cardiac and/or vascular surgical intervention during the current hospitalization
Key inclusion criteria (3 listed)
- Age ≥ 18 years;
- Cardiac and/or vascular surgical intervention during the current hospitalization;
- Signed informed consent from the patient for the use of their anonymized data for scientific purposes.
Key exclusion criteria (3 listed)
- Use of systemic antibacterial drugs within 30 days prior to the surgical intervention;
- Prescription of systemic antibacterial drugs during the hospitalization period for any indication other than hospital-acquired pneumonia;
- HIV infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Not applicable- observational studyNot applicable- observational study | Other | Patients after cardiovascular surgery |
Primary outcome
Hospital acquired pneumonia
Time frame: Within 30 days post-surgery
Occurrence of hospital-acquired pneumonia
Composite cardiovascular and pulmonary endpoint
Time frame: 12 months post-surgery
Occurrence of the composite cardiovascular and pulmonary endpoint
3 secondary outcomes
Non-pneumonia postoperative complications
Time frame: Within 30 days post-surgery
Composite Pulmonary Outcome
Time frame: 12 months post-surgery
Composite Cardiovascular Outcome
Time frame: 12 months post-surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hospital Acquired Pneumonia
RecruitingPhase 4
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Blood Stream Infections, Ventilator Associated Pneumonia
Not yet recruitingPhase 3
Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
Active, not recruiting
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
HAP - Hospital Acquired Pneumonia, VAP - Ventilator Associated Pneumonia
RecruitingPhase 1
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Recruiting
Nosocomial Respiratory Virus Infection
Nosocomial Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Alla A. Boshchenko, MD, PhD, DSc study director
Cardiology Research Institute of Tomsk NRMC
Tatiana P. Kalashnikova, MD, PhD principal investigator
Cardiology Research Institute of Tomsk NRMC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hospital Acquired Pneumonia, run by Tomsk National Research Medical Center of the Russian Academy of Sciences at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alla A. Boshchenko, MD, PhD, DSc (+ 7 (3822)-909055, bosh@cardio-tomsk.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hospital acquired pneumonia (time frame: Within 30 days post-surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.